Phenylketonuria (classic PKU)
Overview
Plain-Language Overview
Phenylketonuria (classic PKU) is a rare inherited condition that affects how the body processes an amino acid called phenylalanine, which is found in many protein-containing foods. It primarily impacts the nervous system because excess phenylalanine can build up in the blood and damage the brain. Without proper processing, this buildup can lead to intellectual disability, developmental delays, and other neurological problems. The condition is caused by a deficiency of an important enzyme called phenylalanine hydroxylase. Early diagnosis and management are crucial to prevent serious health issues. This condition is usually detected shortly after birth through newborn screening tests.
Clinical Definition
Phenylketonuria (classic PKU) is an autosomal recessive metabolic disorder characterized by a deficiency of the enzyme phenylalanine hydroxylase (PAH), which converts phenylalanine to tyrosine. This enzymatic defect leads to toxic accumulation of phenylalanine and its metabolites in the blood and brain, causing neurotoxicity and impaired cognitive development. The disorder results from mutations in the PAH gene. Clinically, untreated PKU presents with intellectual disability, seizures, eczema, and a characteristic musty or mousy odor due to phenylacetate accumulation. Early detection through newborn screening and dietary management can prevent the severe neurological sequelae. The condition highlights the importance of amino acid metabolism in maintaining normal brain function.
Inciting Event
Ingestion of phenylalanine-containing proteins after birth triggers symptom onset.
Absence or severe reduction of PAH enzyme activity due to PAH gene mutations.
Failure to initiate dietary phenylalanine restriction after birth.
Latency Period
Symptoms typically develop within the first few months of life after protein feeding begins.
Newborn screening allows diagnosis before clinical symptoms appear, usually within days to weeks.
Neurologic damage progresses over months to years if untreated.
Diagnostic Delay
Lack of universal newborn screening in some regions delays diagnosis.
Early symptoms like developmental delay and irritability are nonspecific and often misattributed.
Mild or variant forms may have normal early development, leading to delayed recognition.
Failure to consider PKU in infants with hypopigmentation and eczema.
Clinical Presentation
Signs & Symptoms
Intellectual disability and developmental delay if untreated.
Seizures due to neurotoxicity of phenylalanine metabolites.
Behavioral problems including hyperactivity and autistic features.
Eczema and musty odor as characteristic systemic signs.
Hypopigmentation of hair and skin compared to family members.
History of Present Illness
Progressive developmental delay and intellectual disability in infancy.
Seizures and behavioral problems develop as phenylalanine accumulates.
Presence of eczema and musty or mousy body odor due to phenylalanine metabolites.
Hypopigmentation of skin, hair, and eyes due to decreased melanin synthesis.
Feeding difficulties and vomiting may be reported in early infancy.
Past Medical History
Newborns often have normal birth history with no perinatal complications.
Absence of prior metabolic or neurologic disorders unless previously diagnosed PKU.
History of untreated maternal PKU may be relevant in affected infants.
No prior exposure to phenylalanine-restricted diet before diagnosis.
Family History
Siblings with similar developmental delays or diagnosed PKU due to autosomal recessive inheritance.
Parents are typically asymptomatic carriers of PAH mutations.
Family history of consanguinity increases risk of homozygous mutations.
Rare reports of maternal PKU syndrome affecting offspring if mother is untreated.
Physical Exam Findings
Fair skin and blue eyes due to decreased melanin synthesis from phenylalanine accumulation.
Eczema or dry skin commonly observed in untreated patients.
Musty or mousy body odor caused by phenylacetate buildup.
Microcephaly and growth retardation in severe untreated cases.
Hypertonia or spasticity may be present due to neurotoxicity.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of phenylketonuria is established by detecting elevated blood phenylalanine levels typically >20 mg/dL (1200 µmol/L) on newborn screening. Confirmatory testing includes measurement of phenylalanine to tyrosine ratio and PAH enzyme activity or genetic testing for mutations in the PAH gene. The presence of elevated phenylalanine with low or normal tyrosine levels supports the diagnosis. Newborn screening programs use tandem mass spectrometry or Guthrie bacterial inhibition assay for initial detection. Early diagnosis is critical to initiate treatment and prevent irreversible neurological damage.
Pathophysiology
Key Mechanisms
Deficiency of phenylalanine hydroxylase (PAH) enzyme leads to impaired conversion of phenylalanine to tyrosine.
Accumulation of toxic phenylalanine metabolites causes neurotoxicity and brain damage.
Decreased tyrosine levels result in reduced synthesis of dopamine, norepinephrine, and melanin.
Excess phenylalanine disrupts myelin formation and neurotransmitter balance in the central nervous system.
Elevated phenylalanine competitively inhibits large neutral amino acid transport across the blood-brain barrier.
| Involvement | Details |
|---|---|
| Organs | Liver is the key organ where phenylalanine hydroxylase normally converts phenylalanine to tyrosine, and its dysfunction causes PKU. |
Brain is the organ affected by toxic accumulation of phenylalanine, leading to developmental delay and neurological symptoms. | |
| Tissues | Brain tissue is particularly vulnerable to damage from elevated phenylalanine levels, resulting in intellectual disability if untreated. |
| Cells | Hepatocytes are the primary cells expressing phenylalanine hydroxylase, the deficient enzyme in classic PKU. |
| Chemical Mediators | Phenylalanine accumulates due to deficient hydroxylation, causing neurotoxicity and cognitive impairment. |
Tyrosine levels are decreased as it is a downstream product of phenylalanine metabolism, leading to neurotransmitter deficiencies. |
Treatments
Pharmacological Treatments
Sapropterin dihydrochloride
- Mechanism:
Acts as a synthetic cofactor for phenylalanine hydroxylase, enhancing residual enzyme activity to reduce phenylalanine levels.
- Side effects:
Headache
Rash
Gastrointestinal discomfort
- Clinical role:
Adjunctive
Non-pharmacological Treatments
A lifelong phenylalanine-restricted diet with supplementation of a phenylalanine-free medical formula to prevent neurotoxicity.
Regular monitoring of blood phenylalanine levels to guide dietary adjustments and prevent cognitive impairment.
Early newborn screening to enable prompt diagnosis and initiation of treatment.
Prevention
Pharmacological Prevention
Sapropterin dihydrochloride (BH4 cofactor) to enhance residual phenylalanine hydroxylase activity.
Large neutral amino acid supplements to reduce phenylalanine transport across the blood-brain barrier.
Non-pharmacological Prevention
Newborn screening for early detection and treatment initiation.
Strict low-phenylalanine diet starting in infancy to prevent neurotoxicity.
Regular monitoring of serum phenylalanine levels to maintain therapeutic range.
Avoidance of high-protein foods to limit phenylalanine intake.
Outcome & Complications
Complications
Severe cognitive impairment if dietary treatment is not initiated early.
Seizure disorders refractory to standard antiepileptic drugs.
Psychiatric disorders including anxiety and depression in adolescence.
Neurological deficits such as spasticity and ataxia.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Phenylketonuria (classic PKU) versus Maple Syrup Urine Disease (MSUD)
Phenylketonuria (classic PKU) | Maple Syrup Urine Disease (MSUD) |
|---|---|
Infantile onset typically after a few months with developmental delay and seizures | Neonatal onset with poor feeding, lethargy, and seizures within the first week of life |
Elevated phenylalanine with normal branched-chain amino acids | Elevated branched-chain amino acids (leucine, isoleucine, valine) and characteristic maple syrup odor in urine |
Deficiency of phenylalanine hydroxylase enzyme activity | Deficiency of branched-chain alpha-ketoacid dehydrogenase complex activity |
Phenylketonuria (classic PKU) versus Tyrosinemia Type I
Phenylketonuria (classic PKU) | Tyrosinemia Type I |
|---|---|
Elevated phenylalanine with low tyrosine levels | Elevated succinylacetone and tyrosine levels in blood and urine |
Primarily neurologic and cognitive impairment without early liver failure | Progressive hepatic failure and renal tubular dysfunction in infancy |
Deficiency of phenylalanine hydroxylase enzyme | Deficiency of fumarylacetoacetate hydrolase enzyme |
Phenylketonuria (classic PKU) versus Nonketotic Hyperglycinemia
Phenylketonuria (classic PKU) | Nonketotic Hyperglycinemia |
|---|---|
Elevated phenylalanine with normal glycine levels | Elevated glycine levels in plasma and cerebrospinal fluid with high CSF/plasma glycine ratio |
Developmental delay and seizures presenting after neonatal period | Severe hypotonia, apnea, and seizures presenting in the neonatal period |
Deficiency of phenylalanine hydroxylase enzyme | Defect in glycine cleavage system enzymes |
Phenylketonuria (classic PKU) versus Maternal PKU Syndrome
Phenylketonuria (classic PKU) | Maternal PKU Syndrome |
|---|---|
No maternal PKU history; patient has inherited PKU | Maternal history of untreated phenylketonuria during pregnancy |
Neurologic symptoms and intellectual disability due to patient's own PKU | Congenital microcephaly, heart defects, and growth retardation in infant born to mother with PKU |
Deficient phenylalanine hydroxylase activity in patient | Normal phenylalanine hydroxylase activity in infant; elevated phenylalanine due to maternal transfer |